Susquehanna Fundamental Investments’s Medpace MEDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-24,909
Closed -$7.59M 894
2025
Q1
$7.59M Buy
24,909
+6,889
+38% +$2.32M 0.11% 247
2024
Q4
$5.99M Buy
+18,020
New +$6.11M 0.09% 294
2023
Q4
Sell
-24,264
Closed -$5.88M 224
2023
Q3
$5.88M Sell
24,264
-106
-0.4% -$27.1K 0.38% 76
2023
Q2
$5.85M Sell
24,370
-18,496
-43% -$3.84M 0.21% 132
2023
Q1
$8.06M Hold
42,866
0.19% 148
2022
Q4
$9.11M Buy
42,866
+24,264
+130% +$4.85M 0.16% 192
2022
Q3
$2.92M Buy
+18,602
New +$2.97M 0.05% 482
2022
Q1
$7.26M Buy
44,378
+16,811
+61% +$2.77M 0.14% 204
2021
Q4
$6M Buy
27,567
+9,231
+50% +$1.93M 0.16% 161
2021
Q3
$3.47M Buy
+18,336
New +$3.34M 0.06% 410
2021
Q2
Sell
-16,738
Closed -$2.75M 1721
2021
Q1
$2.75M Hold
16,738
0.05% 533
2020
Q4
$2.33M Buy
16,738
+180
+1% +$22.7K 0.04% 579
2020
Q3
$1.85M Hold
16,558
0.06% 453
2020
Q2
$1.54M Buy
+16,558
New +$1.41M 0.07% 346

Other funds holding MEDP

Susquehanna Fundamental Investments's MEDP Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Medpace (MEDP) in Q2 2025, closing a stake of 24,909 shares — an estimated $7.59M sold.

Susquehanna Fundamental Investments first reported a position in MEDP in Q2 2020 and held it in 14 quarters. The position peaked at $9.11M in Q4 2022. 602 funds tracked by Wall St. Rank hold MEDP as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Medpace position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 24,909 Medpace shares in Q2 2025, an estimated $7.59M.
  • Susquehanna Fundamental Investments first reported a position in Medpace in Q2 2020 and held it in 14 quarters.
  • Susquehanna Fundamental Investments's Medpace position peaked at $9.11M in Q4 2022.
  • 602 funds tracked by Wall St. Rank held Medpace as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.